The sources asked not to be named because the matter is not public. Read More ReckittBenckiser says no longer in talks with Merck Both Merck and Sanofi have an extensive line-up of older products that could be carved out, following similar moves now under way at Pfizer and GlaxoSmithKline to place older products in separate divisions. Pfizer announced last year it planned to separate its business into three units - innovative pharmaceuticals; vaccines, oncology and consumer health; and established products. The U.S. group has not ruled out a full breakup. GSK is starting down a similar path, and CEO Andrew Witty said on Wednesday that he would consider single products or broader divestiture of its established drugs.